Alzheon to Present Nine Scientific Posters at AAIC 2026 Highlighting New Clinical, Imaging, Biomarker, and Long-Term Data for Investigational Alzheimer’s Therapy Valiltramiprosate
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing therapies and diagnostic technologies for Alzheimer’s disease (AD) and other neurodegenerative disorders, has announced that it will present nine scientific posters at the 2026 Alzheimer’s Association International Conference (AAIC), taking place in London, United Kingdom. The extensive scientific program will showcase new analyses of the company’s lead investigational therapy, valiltramiprosate (also known as ALZ-801), including findings from its Phase 3 APOLLOE4 clinical trial, Phase 2 biomarker studies, and long-term extension trials.
The presentations are expected to provide a comprehensive overview of the investigational therapy’s clinical performance, imaging findings, biomarker analyses, long-term safety profile, and potential future role in Alzheimer’s disease treatment. Among the new data to be presented are analyses exploring neurovascular protection, diffusion tensor imaging (DTI), volumetric magnetic resonance imaging (vMRI), plasma biomarkers, sustained efficacy over multiple years, and quantitative systems pharmacology (QSP) modeling evaluating the potential use of valiltramiprosate as an oral maintenance therapy following treatment with anti-amyloid antibody therapies.
Collectively, the presentations highlight Alzheon’s continued efforts to advance precision medicine approaches for Alzheimer’s disease, particularly among patients carrying specific genetic risk factors that influence disease progression and treatment response.
Expanding Scientific Evidence for Valiltramiprosate
The nine presentations represent one of the most comprehensive scientific updates on valiltramiprosate since the completion of the company’s Phase 3 clinical program.
Researchers will present expanded analyses from the APOLLOE4 study, together with findings generated from Phase 2 biomarker investigations and long-term extension studies involving patients who have continued therapy for up to four years.
The scientific program has been designed to evaluate multiple aspects of the investigational therapy beyond traditional clinical outcome measures.
In addition to cognitive assessments, researchers will discuss structural brain imaging, biomarker changes associated with Alzheimer’s disease progression, long-term treatment safety, and computational modeling evaluating future therapeutic strategies.
The breadth of the presentations reflects the growing emphasis within Alzheimer’s disease research on integrating clinical outcomes with biological markers capable of providing deeper insight into disease progression and treatment effects.
Focus on APOE4 Homozygous Patients
A central feature of Alzheon’s development program is its focus on patients carrying two copies of the apolipoprotein E ε4 (APOE4) gene.
Individuals who inherit two APOE4 alleles, commonly referred to as APOE4/4 homozygotes, represent approximately 15 percent of all Alzheimer’s disease patients but face substantially higher genetic risk for developing the disease.
In addition to experiencing increased susceptibility to Alzheimer’s disease, APOE4/4 patients often develop pathology characterized by greater amyloid accumulation and more extensive cerebral amyloid angiopathy (CAA), a condition involving amyloid deposits within blood vessels of the brain.
This vascular pathology creates additional clinical challenges because it increases vulnerability to complications associated with certain anti-amyloid antibody therapies currently approved or under development.
By concentrating clinical development on this genetically defined population, Alzheon seeks to address a significant unmet medical need among patients who may require alternative therapeutic approaches.
An Oral Disease-Modifying Therapy
Valiltramiprosate is currently being developed as an investigational oral therapy designed to modify the underlying disease process in Alzheimer’s disease rather than simply providing temporary symptomatic improvement.
Unlike currently approved anti-amyloid monoclonal antibodies that remove amyloid plaques already deposited within the brain, valiltramiprosate is designed to intervene earlier in the amyloid cascade.
The therapy works by inhibiting the formation of soluble amyloid oligomers, small toxic protein aggregates that are believed to contribute significantly to neuronal dysfunction and cognitive decline during Alzheimer’s disease.
Because the therapy acts upstream in the disease pathway, researchers believe it may reduce production of neurotoxic amyloid species before larger plaque deposits develop.
This mechanism distinguishes the investigational therapy from antibody-based approaches that primarily target existing amyloid plaques.
The oral administration of valiltramiprosate also offers practical advantages compared with intravenous infusion therapies that require regular administration in specialized healthcare settings.
Addressing Neurovascular Safety
One of the major themes of Alzheon’s AAIC presentations involves neurovascular protection.
Patients carrying two APOE4 alleles frequently exhibit extensive cerebral amyloid angiopathy, increasing their susceptibility to amyloid-related imaging abnormalities (ARIA) during treatment with anti-amyloid antibodies.
ARIA encompasses several imaging abnormalities, including cerebral edema (ARIA-E) and cerebral microhemorrhages or superficial siderosis (ARIA-H), which can complicate treatment with certain monoclonal antibody therapies.
Although many ARIA events remain asymptomatic, some patients experience headaches, confusion, seizures, visual disturbances, or other neurological symptoms requiring treatment interruption or discontinuation.
According to Alzheon, expanded analyses from the placebo-controlled APOLLOE4 trial will provide new information regarding neurovascular outcomes and ARIA incidence among patients receiving valiltramiprosate.
These findings may have implications not only for Alzheimer’s disease but also for other neurological conditions characterized by cerebral amyloid angiopathy, including certain patients with Down syndrome and primary cerebral amyloid angiopathy.
Advanced Brain Imaging Analyses
Several presentations will focus on advanced neuroimaging techniques designed to evaluate structural changes within the brain.
Among these are diffusion tensor imaging analyses examining hippocampal microstructure.
The hippocampus plays a critical role in memory formation and is one of the earliest brain regions affected during Alzheimer’s disease.
Diffusion tensor imaging provides information regarding microscopic tissue organization that may detect subtle structural alterations before conventional imaging identifies substantial tissue loss.
Researchers will also present volumetric magnetic resonance imaging analyses evaluating changes in brain volume over time.
Brain atrophy, particularly within the hippocampus, represents an important marker of neurodegeneration and disease progression in Alzheimer’s disease.
By correlating imaging findings with cognitive performance and biomarker measurements, investigators hope to better understand how structural brain preservation relates to clinical benefit.
Plasma Biomarkers and Disease Progression
The scientific program will also include new analyses involving plasma phosphorylated tau 217 (p-tau217), one of the most promising blood-based biomarkers currently under investigation for Alzheimer’s disease.
Elevated plasma p-tau217 levels have been associated with amyloid pathology, tau accumulation, and disease progression.
According to Alzheon, investigators observed significant reductions in plasma p-tau217 among patients receiving valiltramiprosate.
The company believes these biomarker findings, together with imaging and clinical observations, provide additional evidence supporting the therapy’s potential disease-modifying effects.
Researchers will also present analyses correlating biomarker changes with imaging outcomes and clinical measures, providing a more integrated assessment of therapeutic response.
Long-Term Extension Data
Another important component of the AAIC presentations involves long-term follow-up data from extension studies.
Participants who continued treatment following completion of earlier clinical trials have now accumulated up to four years of therapy.
Long-term extension studies are particularly valuable in chronic neurodegenerative diseases because they provide information regarding sustained treatment effects, durability of clinical benefit, and long-term safety.
According to Alzheon, the extension studies demonstrated continued favorable safety findings throughout prolonged treatment.
The company reports that no symptomatic cases of ARIA-E or ARIA-H were observed among APOE4/4 or APOE3/4 participants during treatment extending up to four years.
Although long-term extension studies generally lack placebo comparison groups, they provide important information regarding the practical experience of prolonged therapy in patients receiving investigational treatments.
Evaluating Maintenance Therapy After Antibody Treatment
One of the more innovative presentations planned for AAIC involves quantitative systems pharmacology modeling evaluating valiltramiprosate as a potential maintenance therapy following treatment with anti-amyloid antibodies.
Recently approved antibody therapies such as donanemab and lecanemab effectively reduce amyloid plaque burden but require repeated infusions and ongoing clinical monitoring.
Researchers are increasingly exploring strategies that combine different therapeutic approaches to maximize long-term disease control.
Alzheon’s QSP analysis examines the possibility that patients receiving plaque-clearing antibodies could subsequently transition to oral valiltramiprosate maintenance therapy.
Although based on computational modeling rather than clinical trial results, the analysis explores how sequential treatment strategies might influence long-term amyloid biology and disease progression.
Such approaches represent an emerging area of Alzheimer’s disease research as clinicians seek to optimize therapeutic sequencing.
Company Leadership Highlights Precision Medicine Strategy
Martin Tolar, MD, PhD, Founder, President, and Chief Executive Officer of Alzheon, described the upcoming AAIC presentations as the culmination of more than a decade of focused scientific development.
According to Tolar, the company’s research has consistently targeted one of the greatest unmet needs in Alzheimer’s disease: developing effective therapies for APOE4/4 patients who face both elevated disease risk and increased susceptibility to treatment-related complications associated with anti-amyloid antibodies.
He noted that the presentations span multiple areas of investigation, including Phase 3 efficacy, safety, imaging biomarkers, plasma biomarkers, long-term clinical outcomes, and computational analyses evaluating future treatment strategies.
Tolar also emphasized the company’s commitment to advancing precision medicine by developing therapies tailored to genetically defined patient populations.
Should regulatory approval eventually be obtained, he stated that Alzheon intends to make valiltramiprosate available initially for patients with the greatest unmet need while potentially expanding treatment to broader APOE4 populations over time.
Chief Medical Officer Discusses New Findings
Susan Abushakra, MD, Chief Medical Officer of Alzheon, acknowledged that the Phase 3 APOLLOE4 trial did not achieve its primary endpoint.
However, she indicated that the expanded analyses being presented at AAIC continue to support what the company views as a differentiated therapeutic profile for valiltramiprosate.
According to Abushakra, the additional analyses demonstrated consistent evidence of neurovascular protection, including lower rates of amyloid-related imaging abnormalities compared with placebo across the overall study population.
She also highlighted clinically meaningful improvements involving cognition and brain volume among patients with mild cognitive impairment included in the pre-specified subgroup analyses from both the Phase 3 trial and Phase 2 long-term extension studies.
The company further reports that diffusion tensor imaging analyses demonstrated preservation of hippocampal microstructure, with structural imaging changes correlating with both cognitive outcomes and brain volume measurements.
Abushakra stated that these imaging findings, together with reductions in plasma p-tau217 and favorable long-term safety observations, collectively support continued evaluation of valiltramiprosate as a potential disease-modifying therapy.
The nine presentations scheduled for the 2026 Alzheimer’s Association International Conference represent an important opportunity for Alzheon to provide the scientific community with a detailed overview of its investigational Alzheimer’s disease program. By integrating clinical trial outcomes with advanced imaging, blood biomarkers, long-term follow-up, and computational modeling, the company aims to strengthen understanding of valiltramiprosate’s potential role within the evolving Alzheimer’s treatment landscape.
Although additional clinical evaluation and regulatory review will ultimately determine the therapy’s future, the data presented at AAIC are expected to contribute valuable insights regarding precision medicine approaches for genetically defined Alzheimer’s disease populations.
As research increasingly focuses on individualized treatment strategies that combine genetic risk assessment, biomarkers, and targeted therapeutics, programs such as Alzheon’s continue to expand scientific understanding of how disease-modifying therapies may improve long-term outcomes for patients living with this devastating neurodegenerative disorder.
About ALZ-801
Valiltramiprosate/ALZ-801 is an investigational oral agent currently in Phase 3 development as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease.3-7,9,12 Valiltramiprosate is designed to inhibit the formation of neurotoxic soluble beta amyloid oligomers that contribute to cognitive decline in individuals with AD.4-8,10,15 Preclinical mechanism-of-action studies have demonstrated that ALZ-801 can completely block the formation of these neurotoxic oligomers at the dosage used in Phase 3 clinical trials.3,9,12,14
Valiltramiprosate employs an enveloping molecular mechanism of action intended to prevent the aggregation of soluble amyloid oligomers in the human brain, 14 which are associated with the onset and progression of cognitive impairment in AD patients.3,4,7,9,10 In recognition of its therapeutic promise, valiltramiprosate received Fast Track designation from the U.S. Food and Drug Administration in 2017 for the treatment of Alzheimer’s disease.
Clinical trial data suggest that valiltramiprosate exhibits strong clinical efficacy at the MCI stage, and a favorable safety profile, with no observed increase in the risk of brain vasogenic edema. 1-10,13,15 The initial Phase 3 program for valiltramiprosate targets Early AD patients who are homozygous for the apolipoprotein ε4 allele (APOE4/4), with plans to expand future research to include AD treatment and prevention in individuals carrying one copy of the APOE4 gene.3–10